Making Cell Therapy Science Manufacturable
Cell therapy innovators, including academic institutions, biotechnology companies, and pharmaceutical companies, develop the science. GMP CDMOs execute manufacturing but need well-designed processes. NueCell Bio is the dedicated solution between them. The translation gap is wide, and NueCell Bio provides the resources and expertise needed to successfully transform the science into a product. We are the bridge from idea to therapeutic impact.
Built for the Space Between Discovery and GMP
Cell source decisions, cellular engineering, and manipulation require early decisions that can scale from early discovery to commercial manufacturing.
Reprogramming and gene-editing platforms matched to your biology and target product profile, not chosen for convenience, drawing on decades of hands-on toolbox depth across modalities.
Processes and analytics are built with cGMP-ready raw materials and qualified assays, so GMP technology transfer is a replicate exercise, not a reinvention.
Gap assessments, QbD-driven workflows, and multiple critical-step coverage de-risk the highest-cost decisions before clinical entry.
Five Reasons Cell Therapy Innovators Choose NueCell Bio
-
Unique Depth of Expertise
The NueCell Bio team comprises leaders in the cell therapy field and has unrivaled experience, with over 100 peer-reviewed publications and numerous translational successes across a wide variety of cell therapy modalities.
-
Conduit to GMP Manufacturing
We are uniquely positioned, through our expertise, resources, and technology, to translate science into a product supported by scalable processes and analytics that can be transferred to CDMOs for GMP manufacturing, enabling you to advance a cell therapy concept into human trials.
-
Modality & Technology Expertise
We have expertise across a wide range of cell types and continue to invest in our NueStack platform to maintain our leadership in cell therapy design, engineering, and development. Our technologies are designed and deliver successful programs and increased efficiency.
-
Predictable Cost Structures
While innovation is inherently unpredictable, our proprietary NueStacks, flexible approach, developed through extensive experience, enables us to offer milestone-based programs and cost structures that support financial viability and investor confidence.
-
Patient-Centric Therapy Access
Our proprietary NueStack pre-built and tested modular stacks standardize methods to reduce translational timelines, helping you get to trial and market faster and accelerate patient access to much-needed, life-changing treatments.
By the Numbers
Experience that Shows
2 Days
median response time for new program inquiries; actionable plan, not a sales pitch
26,300 ft2
of purpose-built San Diego facility; under ISO 9001 since launch
20+
recent peer-reviewed publications across iPSC, gene editing, and translational CMC
95%+
right-first-time rate
5
years of successful ISO 9001 certification
40+
projects delivered to date
How NueCell Impacts Innovation and Manufacturing Alike
Innovators
Discover Science
NueStack™
Iterates & Defines
the Process
GMP Manufacturer
Executes at Scale
What innovators gain
-
A defined starting point
-
Milestone-based cost clarity
-
Freedom to choose your CDMO
-
Faster, lower-risk path to GMP
-
Development tailored to your molecule
What CDMOs gain
-
A defined, transfer-ready process
-
Less capacity lost to rework
-
Higher first-pass success
-
A partner, not a competitor
Myths vs. Reality in Cell Therapy Translation
What innovators think it takes, what actually closes the gap, and why most attempts stall. Translation is not a single factor or program element; it is a multidisciplinary, rigorous approach applied across science, quality systems, engineering, and regulatory frameworks. NueCell Bio is focused on delivering for each of our innovators.
